瑞舒伐他汀对高龄合并糖尿病冠心病患者调脂作用及安全性分析  

Lipid Modulation and Safety Analysis of Rosuvastatin in Treatment of Senile Diabetes Patients with Coronary Heart Disease

作　　者：刘继红[1] 王桂[2] 李慧颖[3] 冯双[4] 

机构地区：[1]山东省医学科学院附属医院心血管内科,济南250031 [2]济南市长清区人民医院心血管内科,济南250031 [3]山东省医学科学院附属医院特检科,济南250031 [4]淄博市临淄区人民医院口腔科,山东淄博255400

出　　处：《解放军医药杂志》2017年第10期95-97,共3页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：山东省医药卫生科技发展计划基金资助项目(2013WS0371)

摘　　要：目的探讨瑞舒伐他汀对高龄合并糖尿病冠心病患者调脂作用及安全性。方法对山东省医学科学院附属医院2014年2月—2015年11月收治的高龄合并糖尿病冠心病76例的临床资料进行回顾性分析,根据治疗方法分为观察组和对照组,每组38例。对照组给予常规治疗,观察组在对照组基础上加用瑞舒伐他汀治疗。比较2组治疗前后血脂水平变化及不良反应发生情况。结果观察组总有效率高于对照组,治疗后血脂水平较治疗前改善且优于对照组,不良反应发生率低于对照组(P<0.05,P<0.01)。结论瑞舒伐他汀治疗高龄合并糖尿病冠心病效果较好且安全性较高。Objective To investigate lipid modulation and safety of Rosuvastatin in treatment of senile diabetes patients with coronary heart disease. Methods Clinical data of 76 senile diabetes patients with coronary heart disease admitted during February 2014 and November 2015 was retrospectively analyzed, and the patients were divided into ob-servation group and control group （ n=38 for each group） according to therapeutic methods. Control group was treated with conventional therapy, while observation group was added with Rosuvastatin on the basis of treatment for control group. Changes of lipid level and incidence condition of adverse reaction were compared before and after treatment in two groups. Results In observation group, total effective rate was significant higher than that in control group; improved condition of lipid level after treatment was better than those before treatment in same group and control group. Incidence rate of adverse reaction was significantly lower in observation group than that in control group （P〈0. 05, P〈0. 01）. Conclusion Rosuvastatin can achieve better effect with high safety in treatment of senile diabetes patients with coronary heart disease.

关 键 词：糖尿病 冠心病 瑞舒伐他汀 调脂药 

分 类 号：R587.23[医药卫生—内分泌]